bioMérieux obtient l'agrément 510(k) de la FDA pour le test innovant VIDAS® TBI (GFAP, UCH-L1), visant à améliorer l'évaluation des patients victimes d'un traumatisme crânien léger

28 May 2024 18:01 CEST

Subscribe
Issuer

BIOMERIEUX

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1257723_CP_bioMrieux_VIDAS_TBI_FDA_Agrment_20240528.pdf

Source

BIOMERIEUX

Provider

Les Echos

Company Name

BIOMERIEUX

ISIN

FR0013280286

Symbol

BIM

Market

Euronext

Attachments

  • Original Link
  • Permalink

Disclaimer

BioMérieux SA published this content on 28 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 May 2024 16:07:03 UTC.